Any current/future new fundraising through debt or equity?

Krsnaa Diagnostics is entering a significant expansion phase which involves capital expenditure of around INR 500 crores in FY '27. This capex will be funded through a combination of internal accruals and debt. It is noted that the company has started taking on debt; earlier, Krsnaa had no debt. Specific details on new fundraising through equity were not mentioned in the provided text. Management highlighted prudent financial management and a strong leadership team to deliver growth and value. Any further queries on financial specifics can be directed to the Company Secretary, Mr. Sujoy Bose.

Any current/future capex/capital investment/strategic investment?

Rajasthan capital expenditure: Capitalization to happen from Q1 FY '27, around INR 200 crores. Total INR 500 crores capex planned for FY '27, combining Rajasthan (~INR 300 crores), MRI projects (~INR 150 crores), and smaller projects in Jharkhand and Ranchi. This INR 500 crores represents capitalization expected in FY '27, involving a mix of debt and internal accruals. MRI center expansion in Maharashtra includes adding around 10 new MRI centers in the coming quarter (part of a total of 17 centers). Additional small projects and PPP opportunities under implementation and selective new projects

Future growth expectations in sales/revenue/volumes?

Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed. Radiology revenue growth anticipated in FY '27, with 10 new MRI centers added in Q1 and 7 more in pipeline, totaling ~260 radiology centers by FY '27 end. Retail diagnostics is a strong growth driver; retail contribution grew to about 8% in FY '26 and is targeted to scale to 25-30% of total revenue over 3-5 years. Touchpoints in retail network are growing quarter-on-quarter, with 3,500+ collection points and 500+ franchises nationally. Organic like-to-l

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '27 expected to see decent scale improvements and at least maintain EBITDA margins, with potential upside from multiple growth levers. Rajasthan project capitalization from Q1 FY '27 with INR 200+ crore capex expected to contribute positively; some initial depreciation and interest costs to impact margins modestly. Radiology expansion underway with 10 new MRI centers in Q1 FY '27 and total of 17 centers planned, driving future revenue growth. Retail segment targets contributing 25%-30% of group revenue over 3-5 years, indicating long-term growth focus. RPL segment expected to move from marg

Current/ Expected Orderbook/ Pending Orders?

Current pipeline includes a couple of PPP projects under implementation, with no major new orders announced yet. Radiology expansion is ongoing with around 10 MRI centers being added in the current quarter and 7 more planned in coming quarters (total 17). Expected pathology lab network to reach approximately 297 centers by Q2 FY '27, including Rajasthan additions. Rajasthan project is under implementation, with major installations expected to complete by Q2 FY '27. No significant new PPP tender pipelines disclosed for FY '27; growth is expected to be calibrated given current capex and

IN US

Sale is live|00:00:00left today

Krsnaa Diagnostics LtdQ1 FY26Healthcare Services

Krsnaa Diagnostics Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 23.6Market Cap: ₹1.9K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed.
→Radiology revenue growth anticipated in FY '27, with 10 new MRI centers added in Q1 and 7 more in pipeline, totaling ~260 radiology centers by FY '27 end.
→Retail diagnostics is a strong growth driver; retail contribution grew to about 8% in FY '26 and is targeted to scale to 25-30% of total revenue over 3-5 years.
→Touchpoints in retail network are growing quarter-on-quarter, with 3,500+ collection points and 500+ franchises nationally.
→Organic like-to-like growth on existing PPP projects is around 13% annually.
→New PPP project pipelines are under consideration with announcements expected by end Q1 FY '27.
→EBITDA margins expected to be maintained or marginally improve by year-end FY '27 despite some upfront costs in expansion areas.

Margin guidance

Category 3

→FY '27 expected to see decent scale improvements and at least maintain EBITDA margins, with potential upside from multiple growth levers.
→Rajasthan project capitalization from Q1 FY '27 with INR 200+ crore capex expected to contribute positively; some initial depreciation and interest costs to impact margins modestly.
→Radiology expansion underway with 10 new MRI centers in Q1 FY '27 and total of 17 centers planned, driving future revenue growth.
→Retail segment targets contributing 25%-30% of group revenue over 3-5 years, indicating long-term growth focus.
→RPL segment expected to move from marginally negative EBITDA in FY '26 to positive EBITDA in FY '27, aiming to reach consolidated EBITDA levels.
→Conservative revenue guidance for Rajasthan (~INR 100-150 crore in FY '27) with aspirations to scale further.
→Dividend of INR 2 per share declared, reflecting confidence in cash flows and profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Krsnaa Diagnostics is entering a significant expansion phase which involves capital expenditure of around INR 500 crores in FY '27.
→This capex will be funded through a combination of internal accruals and debt.
→It is noted that the company has started taking on debt; earlier, Krsnaa had no debt.
→Specific details on new fundraising through equity were not mentioned in the provided text.
→Management highlighted prudent financial management and a strong leadership team to deliver growth and value.
→Any further queries on financial specifics can be directed to the Company Secretary, Mr. Sujoy Bose.

Order book

→Current pipeline includes a couple of PPP projects under implementation, with no major new orders announced yet.
→Radiology expansion is ongoing with around 10 MRI centers being added in the current quarter and 7 more planned in coming quarters (total 17).
→Expected pathology lab network to reach approximately 297 centers by Q2 FY '27, including Rajasthan additions.
→Rajasthan project is under implementation, with major installations expected to complete by Q2 FY '27.
→No significant new PPP tender pipelines disclosed for FY '27; growth is expected to be calibrated given current capex and project pipeline.
→Board and management are selective about new PPP projects, focusing on long-term value creation rather than aggressive bidding.
→Maharashtra radiology centers in implementation with some delayed installations; revenues expected this year.
→Overall, pipeline is actively managed with focus on quality and sustainable growth rather than volume of orders.

Capex plans

Yes

→Rajasthan capital expenditure: Capitalization to happen from Q1 FY '27, around INR 200 crores.
→Total INR 500 crores capex planned for FY '27, combining Rajasthan (~INR 300 crores), MRI projects (~INR 150 crores), and smaller projects in Jharkhand and Ranchi.
→This INR 500 crores represents capitalization expected in FY '27, involving a mix of debt and internal accruals.
→MRI center expansion in Maharashtra includes adding around 10 new MRI centers in the coming quarter (part of a total of 17 centers).
→Additional small projects and PPP opportunities under implementation and selective new projects being pursued cautiously.
→Upfront manpower deployment for Rajasthan (~5,000 people) will impact near-term costs.
→Capital investment focused on strategic growth in existing and new business verticals like pathology, radiology, and retail diagnostics.

How does Krsnaa Diagnostics Ltd rank vs peers in Healthcare Services?

Pro feature

1Krsnaa Diagnostics Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Krsnaa Diagnostics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio